Sign in
Active, not recruitingPhase 2/3

A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy

Key facts

Who runs it
BeOne Medicines
Where
Granada Hills, Las Vegas, Minneapolis, and Palo Alto, United StatesSee the 4 sitesAlso in 10 other countries, 49 sites
Trial code
Status
Active, not recruiting
Phase
Phase 2/3
People taking part
178 people enrolled
Started
17 Apr 2023
Expected to end
Oct 2027
Type of study
Interventional, 4 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Zanubrutinib
  • Tacrolimus
Record updated
11 September 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Biopsy-confirmed PMN within 5 years before the initial screening (ie, the day the informed consent is signed)
  • UPCR (based on 24-hour urine collection) > 3.5 at initial screening and at confirmation assessment
  • Treatment with a maximally tolerated or allowed dose of an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) for ≥ 24 weeks before randomization (12 weeks before initiation of study drug for Part 1) and with adequate blood pressure control (blood pressure < 130/80 mmHg, measured on ≥ 2 occasions [not on the same day] within 4 weeks before the assignment of study treatment)
  • Anti-PLA2R antibody > 50 RU/mL at confirmation assessment (Part 1 only)

Who cannot take part

  • A known history of a primary immunodeficiency or an underlying condition such as human immunodeficiency virus (HIV) infection or splenectomy that predisposes the participant to infections
  • Patients at risk for tuberculosis at screening
  • Known infection with serologic status reflecting active or chronic hepatitis B virus infection, or presence of hepatitis C virus antibody
  • Severe hepatic insufficiency (Child-Pugh C)
  • Clinically significant cardio-cerebrovascular diseases; Note: Other protocol defined Inclusion/Exclusion criteria may apply
  • Type 1 or 2 diabetes mellitus with hemoglobin A1c (HbA1c) ≥ 7% at screening
  • Severe renal disease as determined by rapid decline in eGFR (defined as > 15 mL/min/1.73m\^2 within 24 weeks prior to randomization, not otherwise explained)
  • Participants with a secondary cause of membranous nephropathy

Where in United States

Also in 10 other countries, 49 sites

  • Amicis Research CenterGranada Hills, United States
  • Kidney Specialist of Southern Nevada (Ksosn)Las Vegas, United States
  • Intermed ConsultantsMinneapolis, United States
  • Stanford UniversityPalo Alto, United States

About the trial

What the trial wants to find out

The primary objectives of this study are: In Part 1 to evaluate the efficacy of zanubrutinib as measured by proteinuria reduction, and in Part 2 to evaluate the efficacy of zanubrutinib compared with tacrolimus as measured by complete remission rate, in participants with primary membranous nephropathy (PMN) who are on optimal supportive care.

The 4 groups in the trial

  • Part 1: Zanubrutinib High DoseTreatment being tested

    Participants will receive zanubrutinib twice daily.

    Treatment: Zanubrutinib

  • Part 2: Zanubrutinib High DoseTreatment being tested

    Participants will receive zanubrutinib twice daily.

    Treatment: Zanubrutinib

  • Part 2: Zanubrutinib Low DoseTreatment being tested

    Participants will receive zanubrutinib once daily.

    Treatment: Zanubrutinib

  • Part 2: TacrolimusExisting treatment, for comparison

    Participants will receive tacrolimus capsules twice daily for 64 weeks.

    Treatment: Tacrolimus

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 2/3, Multicenter, Randomized, Active-Controlled, Open-label Study to Evaluate the Efficacy and Safety of Zanubrutinib in Patients With Primary Membranous Nephropathy
Publications
Record updated
11 September 2026